cetirizine dinitrate

BLX000441-002 is a liposomal nasal spray formulation of cetirizine dinitrate, a second-generation, selective H1-antihistamine. Developed by the Swedish biopharmaceutical company Biolipox AB (later acquired by Orexo), the drug is intended for the treatment of seasonal allergic rhinitis. By utilizing a liposomal delivery system for intranasal administration, BLX000441-002 aims to provide a faster onset of action and improved local tolerability compared to traditional aqueous nasal sprays or oral antihistamines, while also reducing systemic exposure and associated side effects. The compound was evaluated in Phase 2 clinical trials, specifically assessing its time to onset of action using histamine-induced nasal plasma exudation as a biomarker.

Other names

cetirizine dinitrate